

Tissue Transglutaminase in normal & abnormal wound healing

Review article

†E Verderio,*T Johnson and †♦M Griffin

†School of Science, Nottingham Trent University, Clifton Lane, NG11 8NS Nottingham,
*UK, Sheffield Kidney Institute, Sheffield University Division of Clinical Science,
Northern General Hospital, Herries Road, Sheffield S5 7AU, UK

♦ Corresponding Author

Summary

A complex series of events involving inflammation, cell migration and proliferation, ECM stabilisation and remodelling, neovascularisation and apoptosis are crucial to the tissue response to injury. Wound healing involves the dynamic interactions of multiple cells types with components of the extracellular matrix (ECM) and growth factors. Impaired wound healing as a consequence of aging, injury or disease may lead to serious disabilities and poor quality of life. Abnormal wound healing may also lead to inflammatory and fibrotic conditions (such as renal and pulmonary fibrosis). Therefore identification of the molecular events underlying wound repair is essential to develop new effective treatments in support to patients and the wound care sector.

Recent advances in the understating of the physiological functions of tissue transglutaminase a multi functional protein cross-linking enzyme which stabilises tissues have demonstrated that its biological activities interrelate with wound healing phases at multiple levels. This review describes our view of the function of tissue trasnglutaminase in wound repair under normal and pathological situations and highlights its potential as a strategic therapeutic target in the development of new treatments to improve wound healing and prevent scarring.

Keywords: tissue transglutaminase, wound healing, fibrosis, fibronectin, collagen.

Overview of wound healing

Wound healing is characterised by three interrelated and overlapping phases: inflammation, tissue formation/stabilisation and tissue remodelling. It is a complex and dynamic process involving the interactions of different cell types that vary depending on the type of tissue involved. It employs an intercalating array of signalling peptides such as growth factors and cytokines that control and regulate a co-ordinated cellular and extracellular matrix remodelling to repair the lesion. For example, following injury to the skin, which is probably the most well characterised process (Singer and Clark 1999; Harding et al 2002 [and references therein]), the wound is normally filled by a blood clot which re-establishes hemostasis and serves as a temporary matrix for the migration of cells from adjacent tissue. It consists mainly of transglutaminase-mediated (factor XIIIa) cross-linked fibrin with incorporated plasma fibronectin (FN). In particular FN acts as a provisional matrix for cell migration and cell adhesion by interaction of its epitopes with trans-membrane receptors. These are predominantly the integrin class of receptors, which mainly recognise the ArgGlyAsp (RGD) epitope within the FN type III₁₀ domain and the heparan sulfate proteoglycans (HSPG) class of receptors (primarily syndecan-4), which mainly bind the FN C-terminal HepII epitope (Burrige and Woods and Couchman 2001). Cells within the thrombus, predominantly activated platelets, release many wound healing mediators (such as platelet-derived growth factor, PDGF) leading to the inflammatory response by the recruitment and activation of macrophages and fibroblasts. Macrophages have a key role in phagocytosis of microorganisms and remnants of the ECM and in the secretion of wound healing cytokines such as PDGF, vascular endothelial growth factor (VEGF) and also transforming growth factor β (TGF- β) and basic and acidic fibroblast growth factor (FGF), which mediate the transition between inflammation and tissue repair. Fibroblasts are key cells in the formation of new tissue in the wound space. After migrating into the wound area, they synthesise new ECM with gradual replacement of the provisional matrix with a collagen matrix. Several matrix metalloproteases (MMPs) and tissue inhibitors of matrix metalloproteases (TIMPs) are expressed during wound healing and are responsible for matrix remodelling by degrading existing matrix in/around the wound edge and by creating a path for cell migration while

new matrix is deposited (McCawley and Matrisian 2001). Matrix degradation is also thought to lead to the release of protein fragments that provide novel biological activities within the injury site important to facilitate repair (Davis et al 2000). Fibroblasts subsequently assume a myofibroblast phenotype, express α -smooth muscle actin and initiate tissue compaction and wound contraction.

Endothelial cells, stimulated by the local secretion of angiogenic factors such as those belonging to the epidermal growth factor family (EGF) and the FGF family, are responsible for the neovascularization in the wounded area in the granulation tissue thus supporting the nutritional requirement of proliferating keratinocytes and fibroblasts. During the transition from granulation to scar tissue collagen is continuously remodelled with the formation of large collagen bundles and intermolecular crosslinks. Fibroblasts stop producing collagen and the granulation tissue is replaced by a scar, which is a relatively a-cellular matrix (Singer and Clark et al 1999). This decrease in cellularity is mediated by apoptosis (Desmouliere et al 1995). Many new blood vessels formed to sustain the granulation tissue are also eliminated as a result of apoptosis (Singer and Clark 1999).

This brief description of wound healing demonstrates the wide array of molecular and cellular events underlying this process.

Tissue transglutaminase adds to the families of genes implicated in wound healing

In recent years, targeted disruption of genes encoding for growth factors and ECM components has revealed novel and specific roles in wound healing for a wide range of gene families. An example for this is demonstrated by targeted disruption of thrombospondin genes (TSP1 and TSP2), which has highlighted their function in the angiogenesis and inflammation steps of the wound healing process. Excisional wounds of TSP2-null mice are characterized by increased neovascularization and heal at an accelerated rate, suggesting a role for TSP2 in angiogenesis inhibition (Kyriakides et al 1998; Agah et al 2002). In contrast, absence of TSP1, a potent chemotactic factor for inflammatory cells, leads to delayed wound healing (Agah et al 2002; Bornstein and Sage 2002). Delayed skin wound healing has been observed in mice lacking FGF2 (basic

fibroblast growth factor) and mice deficient in MMPs display impaired wound repair (McCawley and Matrisian 2001). Delayed wound healing has been reported in TGF- β_1 deficient mice lacking T and B cells (Crowe et al 2000). Recently, alteration of the FN alternatively splicing in mice has demonstrated that while disruption of the FN gene is lethal mice, animals devoid of EDA exon (extra domain A) display abnormal skin wound healing and both mice with complete exclusion or constitutive inclusion of the EDA exon have shorter lifespan than wild-type mice, possibly because defective wound repair (Muro et al 2003).

A novel component of the cell/tissue response to cell damage and stress is tissue transglutaminase (tTG; TG2; EC2.3.2.13), a multifunctional protein which modulates cell-matrix interactions, tissue stability and a variety of cell functions (Aeschlimann and Thomazy 2000; Griffin et al 2002; Fesus and Piacentini 2002; Lorand and Graham 2003). A definitive role for tTG in tissue repair, which is the main focus of this review, has been recently confirmed in tTG-deficient mice (Nanda et al 2001; De Laurenzi and Melino, 2001) which presented with impaired skin wound healing (Mearns et al 2002). Tissue transglutaminase is the first described member of the transglutaminase family, which so far includes nine members. Unlike other transglutaminases, tTG is characterised by unique structural features which leads to a wide range of biological activities and physio/pathological implications. Although some controversy and redundancy of information is present on the definitive functions of tTG, rapid advances have been made in the past few years and a triple mechanism of action for tTG (protein transamidation activity; GTPase activity; structural adhesion activity) can be proposed. tTG is characterised by a papain-like catalytic triad (CysHisAsp) responsible for a Ca²⁺-induced transamidating activity which catalyses a range of tTG-mediated reactions leading to post-translational modifications of proteins, of which the cross-linking of proteins by ϵ -(γ -glutamyl)lysine bonds is probably the most frequent (Lorand and Graham 2003). Integrated with the Ca-regulated transamidase active site is a GTP binding and hydrolysis site, which is responsible for the G-protein/signal transduction function of tTG, which for this role is also known as Gh α . Binding of GTP negatively regulates the protein transamidation activity of tTG by inducing a conformational change that blocks the

access of substrates to the transamidating active site (Liu et al 2002). Reciprocally, the binding of Ca^{2+} inhibits the binding of GTP. Tissue transglutaminase is expressed ubiquitously and the expression level depends on the type of tissue. Typically, high levels of tTG can be found in cells naturally subject to insult such as endothelial cells and mesangial cells (Fesus and Thomazy 1988).

tTG is localised in three major cell compartments (cytosol, plasma membrane and nucleus) and unlike other transglutaminases is secreted and deposited in the ECM. The mechanism of secretion is unusual because tTG lacks a signal peptide and is not secreted by a classical endoplasmic reticulum/Golgi-dependent mechanism. It is known that tTG secretion requires the active-state conformation of tTG (Balklava et al 2002) and an intact N-terminal FN binding site (Gaudry et al 1999) but due to its atypical secretion mechanism, tTG is not efficiently released. However its release dramatically increases in situations of tissue damage and cellular stress (Upchurch et al 1991, Johnson et al 1999, Haroon et al 1999) when it accumulates in the ECM initially in complex with FN. The protein cross-linking activity of tTG is tightly regulated both inside the cell, by the Ca/GTP:GDP ratio and outside the cell by matrix binding and red-ox state of the Cys active site (Verderio et al 2003; Cocuzzi and Chung 1986). An *in situ* transglutaminase activity assay based on small-size fluorescent primary amine substrate has clearly shown that tTG is in a catalytically active state while present at the cell surface. In contrast, the tTG transamidating activity would be mostly latent intracellularly (Smethurst and Griffin 1995; Verderio et al 1998). More recently, a cross-linking independent “structural” function of TG has been found in the extracellular space by many authors (Akimov et al 2000; Balklava et al 2002; Verderio et al 1993).

Due to its multiple activities and cellular distribution, tTG can potentially target the tissue repair process at multiple levels. The complex interrelations between the actions of tTG and the repair process are schematically depicted in Fig.1 and described in the next sections.

Secretion of tTG in response to tissue injury and stress

During tissue injury cells in the wound site are induced to synthesise and release molecules which participate in the regulation of the tissue injury response. These are typically ECM components such as osteopontin, SPARC, thrombospondins alternatively spliced FNs and collagen (Davis et al 2000). Studies on skin by Bowness et al (1988) reported increased transglutaminase activity during wound healing in rats. At the cellular level, Upchurch et al (1991) demonstrated binding of endogenous tTG to the ECM following puncture wounding a fibroblast cell monolayer and persistence of tTG around the wound area for many hours afterwards. Haroon et al (1999) reported not only an increase in tTG activity but also an increase in tTG expression by day 3 post-wounding following punch biopsy wounds in rats. Immunohistochemical detection of TG expression (with the monoclonal anti-tTG antibodies TG100 and Cub7402 at concentrations which are non reactive to factor XIIIa) and its isopeptide bond activity product (814 MAM CovalAb) during rat dermal wound healing showed that tTG is expressed and active in endothelial cells, macrophages and skeletal muscle cells in all stages of wound healing (Haaron et al 1999).

Therefore tTG adds to the list of matrix components that are induced following tissue injury. Evidence is provided by the literature of regulation of tTgase expression by cytokines implicated in the repair process such as transforming growth factor β_1 (TGF- β_1), interleukin-6 (IL-6), tumor necrosis factor α (TNF- α) (George et al 1990; Suto et al. 1993; Ikura et al 1994; Kuncio et al 1998). TGF- β_1 plays a central role in the wound response acting at a multiplicity of levels and influencing the inflammatory response, ECM deposition and remodelling and angiogenesis (Shah et al 1999). IL-6 is an important inflammatory cytokine whose suppression in transgenic mice leads to impaired wound repair (Gallucci et al 2000). TNF- α is mainly released by neutrophils and leads to pleiotropic expression of growth factors. Evidence for tTG regulation by cytokines is sustained at the molecular level by the isolation of the regulatory regions of the tTgase gene (Ritter and Davies 1998). Our recent work suggests that cell stress resulting from a number of external stimuli can result in the regulated release of tTG from cells. For example, exposure of Swiss 3T3 fibroblasts to the mitochondrial dysfunction agent 3

nitropropionic acid (3-NP) leads to early stress induced release of tTG prior to release of the intracellular marker lactate dehydrogenase. [Li *et al* 2002]

We have also recently reported that many of the stress factors e.g. hyperglycaemia [Skill *et al* 2003], acidosis (Johnson *et al* 2002) and hypoxia (Fisher *et al* 2002) associated with the progressive deterioration of kidney function and architecture can also lead to changes in cellular distribution of tTG in a number of different kidney tubular epithelial cell lines. As with 3-NP induced release of tTG which is subsequently found at the cell surface and in the extracellular matrix appears to be a controlled and regulated process. Interestingly, in these tubular epithelial cell lines potential inducers of tTG such as TGF β ₁, TNF α , IL-1 β , retinoic acid and dexamethasone fail to alter tTG expression (Johnson *et al* 2002) raising questions as which stress factors lead to cellular release of the enzyme. Studies in liver fibrosis suggest that NFK β (Mirza *et al* 1997) may be a key player but little of the upstream signalling was defined.

Role of tTG in the cell-extracellular matrix events important in wound repair

The entire tissue repair process is regulated by the interaction of cells with the surrounding ECM, thus ensuring cell adhesion, survival and proliferation. (Sechler and Schwarzbauer. 1998; Singer and Clark 1999).

For example the production of FN by fibroblasts along with its cell-surface receptors, is an essential step in the formation of new granulation tissue. FN participates in the regulation of the wound-repair response by providing a provisional matrix prior to collagen deposition which is essential for adhesion, migration and proliferation (Davis *et al* 2000).

Biochemical observations first made by Lorand and confirmed by other authors have clearly demonstrated that FN has a high affinity binding site for tTG which would lie on the N-terminal gelating binding fragment of FN (LeMosy *et al* 1992; Radek *et al* 1993; Gaudry *et al* 1999). tTG appears as a globular protein bound to the N-terminal portion of FN, when visualised by rotary shadowing electron microscopy (LeMosy *et al* 1992).

Many of the extracellular roles of tTG which have implications in the early stages of wound repair involves its interaction with FN.

Our studies and those of other groups have confirmed that tissue transglutaminase is a FN-binding protein in cultured cells (Verderio et al 1998; Gaudry et al 1999) and it is able to modulate the FN matrix by forming non reducible Ca^{2+} -dependent ϵ -(γ -glutamyl)lysine cross-links (Jones et al 1997; Verderio et al 1998). Once released from cells, following cellular damage, inflammation or cell stress (Upchurch et al, 1991; Johnson et al, 1999; Haroon et al, 1999), tTG binds tightly to FN, as we have recently visualised by immunofluorescence and immunogold electron microscopy (Gaudry et al 1999, Verderio et al 1998, Verderio et al 1999). Binding of FN to tTG protects tTG from proteolytic degradation (Belkin et al 2001) and also leads to downregulation of tTG transamidating activity. Conversely, cell-surface tTG modulates and alters FN matrix stability by multimerisation following cell damage (Gross et al 2003). It has also been proposed that by interacting with the gelatin binding domain of FN, tTG may cooperate with $\alpha_5\beta_1$ integrins in the assembly of the FN matrix (Akimov and Belkin 2001).

The cross-linking function of tTG in the extracellular matrix leading to ECM stabilisation/remodelling has been identified in a number of biological processes important for tissue repair (Aeschliman and Thomazy 2000; see also section “tTG and abnormal healing leading to fibrosis and scarring”). However an increasing number of reports indicate that the extracellular function of tTG is not solely dependent on its crosslinking activity, which may be downregulated by matrix binding (LeMosy et al 1992; Verderio et al 2003). tTG participates in cell matrix interactions which are fundamental in the tissue repair process such as cell adhesion, cell spreading and cell movement of fibroblasts. Rather than through increased matrix stability tTG can affect cell-matrix interactions either as an adhesion co-receptor of β_1 and β_3 integrins, or as an independent cell adhesion protein. (Akimov et al 2000; Gaudry et al 1999b; Balklava et al 2002; Belkin et al 2001; Isobe et al 1999). We have also proposed a mechanism whereby tTG function is strictly dependent on its specific association with matrix FN and in this complex tTG would support an RGD-independent cell adhesion process that is not

linked to its transamidating activity (Verderio et al 2003) (also see section “Role of tTG in RGD-independent cell adhesion and cell survival”).

Role of tTG in matrix stabilisation

Cell proliferation, cell movement and cell interactions with matrix active sites depends on a regulated balance between matrix synthesis and matrix degradation. tTG-catalysed ϵ -(γ -glutamyl)lysine cross-links are stable to proteolytical and mechanical damage, therefore confer increased stability and resistance to degradation to the modified extracellular matrix proteins ((Johnson et al. 1999)).

Haroon et al (1999) reported the increased expression of tTG found in endothelial cells and macrophages invading the fibrin clot results in the formation of transglutaminase-mediated cross-linking in both fibrin and the new granulation tissue during wound healing (Haaron et al 1999). This finding is consistent with the observation that human umbilical vein endothelial cells (HUVEC) are a rich source of tTG, the synthesis of which is up-regulated by thrombin. (Auld et al 2001). tTG retains activity in the ECM of HUVEC, contributing to the stability of the matrix (Mitchell et al 2002). Factor XIIIa and possibly tTG are thought to contribute to the cross-linking of plasminogen activator inhibitor 2 (PAI-2) and α 2-antiplasmin, which are inhibitors of fibrinolysis, to different lysine residue of fibrin(ogen), thus further contributing to the stabilisation of the fibrin clot (Ritchie et al 2000). In the epithelial layer tTG is expressed at the dermo-epidermal junctions, where it may serve to attach the epithelial layer to the dermo-epidermal junction (Ragunath et al 1996). The ability of tTG to form non reducible multimers of extracellular matrix FN leading to its stabilisation (Martinez et al 1994, Jones et al 1997; Verderio et al 1998, Gross et al 2003) is also well demonstrated. Exposure of human dermal fibroblasts to non lethal ultraviolet doses (UV) results in increased tTG activity which does not require *de novo* protein synthesis and leads to multimerisation of FN into non reducible high molecular weight polymers. These data are consistent with a role for tTG in the rapid stabilisation of tissue following UVA damage (Gross et al 2003).

Following wounding of a monolayer of Swiss 3T3 cells induced to overexpress tTG, a dramatic increase in tTG cross-linking activity could be measured at the edge of the wound bed by monitoring the incorporation of a fluorescent amine substrate for tTG.

Following wounding massive intracellular crosslinking (detected by incorporation of labelled primary amine) was also evident in both Swiss 3T3 cells and in an endothelial cell line ECV304 which has high constitutive levels of tTG (Fig. 2). It is likely that this increased activity of tTG both in the intracellular and extracellular environment would lead to *in vivo* stabilisation of the wound area. Increased multimerisation by tTG may serve to stabilise the matrix and/or increase matrix valency thus enhancing cell-matrix interactions such as cell adhesion and migration in the wound area to promote wound healing.

Other members of the TG family which are likely to contribute to the stabilisation of the provisional matrix are factor XIIIa, and also epidermal transglutaminase, which is expressed in keratinocytes and other epithelial-derived cells (Lorand and Graham 2003). However, unlike factor XIIIa, tTG does not require thrombin activation and therefore could continue to serve as a matrix stabiliser in the absence of thrombin when the latter is removed from the site of injury.

We have reported that increased tTG expression in Swiss3T3 fibroblasts using a tetracycline-regulated system, leads to an increased pool of FN fibrils compared to non-induced cells expressing low background level of tTG, suggesting that modulation of tTG expression affects the insoluble FN fraction. The increased FN deposition in this cell model may result from increased matrix stabilisation, since Swiss3T3 cells overexpressing TG display a fourfold increase in $\epsilon(\gamma\text{-glutamyl})\text{lysine}$ crosslink when compared to the noninduced cells, which is likely to be mostly formed extracellularly (Verderio et al 1998).

During the transition from granulation tissue to scar, tissue remodelling plays a key role and depends on the balance between the synthesis and degradation of collagen (Singer and Clark 1999). Collagen remodelling leads to the formation of large bundles with the creation of new intermolecular crosslinks, which give tensile strength to the scar. We have demonstrated using *in vitro* studies that collagen I when cross-linked either in the presence or absence of FN by tissue transglutaminase leads to increased stability to MMP-1 (Johnson et al 1999). Apart from collagen 1, tissue transglutaminase has been

shown to cross-link a number of different types of collagen (II, III V XI) and other ECM proteins (Aeschlimann *et al* 1996; Aeschlimann and Thomazy 2000; Nomura *et al* 2001; Griffin *et al* 2002; Lorand and Graham 2003).

Crosslinking-independent roles of tTG in cell migration

FN and fibrin provide a provisional matrix for the concomitant migration of inflammatory cells, fibroblasts and endothelial cells (Singer and Clark 1999).

The contribution of tTG to cell adhesion and migration has now been defined in a number of different cell systems. For example, induction of tTG expression in Swiss 3T3 fibroblasts transfected with the catalytically active and inactive tTG (cys²⁷⁷ ser mutant) under control of the tet regulatory system (Verderio *et al* 1998) is accompanied by a decrease in cell migration on FN (Balklava *et al* 2002) when cell motility was assayed by measuring outward cell migration from an agarose droplet on FN (Balklava *et al* 2002). This data suggest that the crosslinking activity of tTG is not responsible for the observed effect of tTG on cell motility.

In agreement with these data, assays of in vitro wound closure tests revealed a slower rate of migration of tTg transfected Swiss3T3 fibroblasts when induced to over-express tTG compared to cells expressing a low background level of tTG (Fig. 3). In addition the ability of anti-tTG monoclonal antibody Cub7402 to reduce cell migration in a dose-dependent manner (Balklava *et al* 2002) indicates that cell-surface tTG is an important component in the migration of cells. Indeed incubation of cells with Cub 7402 leads to loss or reduction of cell attachment in these (Verderio *et al* 1998) and other cell types (Jones *et al* 1997; Heath *et al* 2001), in a similar manner as described for cells incubated with antibodies directed against cell surface integrin receptors β_1 and α_5 (Fogerty *et al* 1990). In a different cell system Akimov and Belkin (2001b) have demonstrated that tTG, which is expressed on the surface of monocytic cells, is also involved in the adhesion and migration of monocytic cells on a FN matrix. During the differentiation of monocytes into macrophages tTG expression is increased.

These in vitro models are likely to represent only a fraction of a more complicated mechanism in vivo. However, as previously referred to, initial in vivo studies on wound healing using punch biopsy-induced skin lesions appear to show a significant delay in wound closure in tTG-deficient mice compared to control wild type littermates (Mearns et al 2002).

Role of FN-bound tTG in mediating RGD-independent cell adhesion and cell survival

During tissue injury when the composition of the ECM and its molecular structure are altered in several significant ways, modulation of cell adhesion as a result of matrix alterations, may be an important step in wound-repair responses, which involves the dynamic interactions of multiple cells types with the extracellular matrix (ECM) (Davis et al 2000).

In a recent study (Verderio et al 2003) we demonstrated that matrices of FN in complex with tTG, prepared either in vitro using purified proteins, or by cell-secretion forming a physiological ECM (tTG-FN), have a distinctive adhesive role. In response to tTG-FN, various cell types (e.g. fibroblasts, osteoblasts and endothelial-like cells) could largely restore loss of cell adhesion following inhibition of the classical FN ArgGlyAsp (RGD)-dependent adhesion pathway mediated by $\alpha_5\beta_1$ integrin receptors. In contrast, the simple binding of purified guinea pig liver tTG to either tissue culture plastic or the gelatin binding domain of FN, which contains the tTG binding site, did not enhance cell adhesion, which requires the specific complexation of tTG with FN. This matrix complex was sufficient to support the formation of focal contacts in the presence of RGD peptide, which are visualised by indirect fluorescent staining of vinculin in Fig. 4, and the assembly of associated actin stress fibers (Verderio et al 2003). Inhibition of RhoA by C3-exotransferase completely blocked RGD-independent formation of actin stress fibers by tTG-FN. A PKCa inhibitor (Gö6976) (Gschwendt et al 1996), negatively affected RGD-independent cell adhesion to tTG-FN, suggesting the involvement of PKCa. Analysis of focal adhesion kinase (FAK) activation implicated an enhanced tyrosine phosphorylation of FAK during this process.

We have no evidence so far of a direct activation of FAK by PKC α in response to tTG-FN. Recently it was shown that activation of RhoA stimulates FAK Tyr₃₉₇ phosphorylation and that PKC activity is not involved in this process (Wilcox-Adelman et al 2002). However it was also proposed that both pathways, PKC and Rho are separately required for full cell adhesion (Woods and Couchman 2001 [and reference therein]).

At this stage it is still not entirely clear how these intracellular mediators convey signals from the extracellular tTG-FN.

Cell adhesion to tTG-FN is not linked to the intrinsic tTG ability to modify the FN matrix by calcium-dependent transamidation, which is consistent with the previously described transamidating-independent role for tTG in cell-matrix interactions (Belkin et al 2000; Balklava et al 2002). Treatment of HOB cells with heparitinase, an enzyme that catalyses the eliminative cleavage of heparin and heparan sulfate, greatly diminish the RGD-independent adhesion in response to tTG-FN, suggesting that cell-surface HSPGs may mediate RGD-independent cell adhesion to tTG-FN

It is accepted that the RGD-mediated cell adhesion plays a central role in cell survival and synthetic peptides containing the RGD motif induce apoptosis in many cell types, by acting as competitive inhibitors of FN-integrin interaction and activators of caspase 3 (Hadden and Henke 2002; Buckley et al 1999).

The observation that tTG-FN can rescue tTG-null primary dermal fibroblasts from detachment-induced apoptosis mediated by RGD peptide is consistent with the finding that RGD-independent cell adhesion to tTG-FN is linked to the intracellular cell survival kinase FAK (Frisch et al 1996; Frisch and Sreaton. 2001).

Such a complex of tTG and FN may be necessary to ensure adhesion-mediated cell survival in situations of cell wounding or cell stress, where the increased expression of matrix-degrading metalloproteinases triggered by the inflammatory response, would lead to fragmentation of the ECM, disruption of cell adhesion-mediated integrin-signalling and finally apoptosis (Kapila et al 1999).

Role of tTG in the inflammatory response

As outlined earlier, thrombus formation re-establishes hemostasis after tissue injury and provides a provisional ECM for cell migration. Trapped platelets within the clot trigger an inflammatory response and secrete wound healing factors such as PDGF that attract macrophages and fibroblasts. Much attention has focused on macrophages, which mediate the transition between inflammation and repair, by the secretion of wound healing mediators such as PDGF, VEGF and other cytokines such as those of the TGF- β and FGF families (Singer and Clark 1999). The tTG antigen was found to be particularly expressed in macrophages, adjacent to the re-epithelialization zone and in the provisional fibrin matrix during rat dermal wound healing (Haaron et al 1999).

By using mice deficient in tTG, Szondy et al (2003) have recently found that lack of tTG in macrophages prevents efficient phagocytosis of dead cells. The phagocytosis of apoptotic cells was defective in the thymus of TG2-deficient mice after induction of apoptosis by either a dose of anti-CD3 monoclonal antibody, a dexamethasone-acetate injection or gamma irradiation. The defect in clearance of dead cells by macrophages leading to increased inflammation was related to the impaired activation of TGF- β_1 , which is specifically released by macrophages on recognition of dead cells and play an important function in downregulating the inflammatory response (Szondy et al 2003).

Crosslinking of intracellular proteins by tTG (see Fig 2), which occurs if the insult produces a loss in calcium homeostasis (Verderio et al 1998; Johnson et al 1998; Nicholas et al 2003), may also be significant to prevent leakage and lysis of dying cells, thus maintaining their structural integrity and the integrity of the tissue within which the damaged cells are dying thus further containing the inflammatory response (Nicholas *et al* 2003).

Inflammation occurs as a defence response to physical damage. The initial local vasodilation and vascular permeability is followed by the release of arachidonic acid from the cell membrane by the enzyme phospholipase A2, which is the rate limiting step in

the biosynthesis of eicosanoids by cyclo-oxygenase (COX). The levels and activities of these lipid mediators have been associated with the regulation of the inflammatory response and a number of pathological states including asthma, pulmonary fibrosis, as well as other inflammatory lung diseases. tTG activity is found to be upregulated in various inflammatory conditions and in diseases which are characterised by mucosal inflammation, such as celiac disease, Crohn's disease, ulcerative colites (Lorand and Graham 2003). The activity of sPLA2s (secretory isoforms of phospholipase A2), a membrane protein which releases arachidonic acid during inflammation, is enhanced by tTG either through the formation of an isopeptide bond within sPLA2 or through its polyamination (Cordella-Miele et al 1990 and 1993). Sohn et al (2003) have recently shown that new chimeric peptides which are derived from pro-elafin and antinflammins, can inhibit sPLA2, tTG activity and tTG-mediated modification of sPLA2 and display strong in vivo anti-inflammatory activity. In a transgenic mouse model overexpression of tTG in ventricular myocytes under the control of a alfa-myosin heavy chain promoter, leads to upregulation of cyclooxygenase-2 (COX-2), thromboxane synthase (TxS) and results in cardiac failure (Zhang et al 2003).

Role of tTG in neovascularisation

Neovascularization is necessary to support the new granulation tissue, which form and invade the wound space after injury. It is a complex and dynamic process involving stimulation of endothelial cells by both serum factors (VEGF, FGF, TGF- β) and the ECM environment in the wound bed. The migration of endothelial cells and the formation of new vessels is affected by the composition of both the granulation tissue and the endothelial basement membrane (Zhang and Kirsner 2003).

Following injury tTG is externalised, binds to the ECM and affects both the stability and structure of the ECM by virtue of its dual cross-linking and structural role. By modulating matrix storage of latent TGF- β_1 , tTG participates in the activation of this important wound healing cytokine (Taipale et al 1994; Kojima et al 1993; Nunes et al 1997; Verderio et al 1999). All these tTG-mediated events are likely to influence angiogenesis during wound repair. Haroon et al (1999) have found that recombinant tTG

enhances blood vessel length density if applied topically in an *in vivo* dorsal skin flap window chamber, suggesting the implication of tTG in promoting angiogenesis in wound repair.

In contrast if tTG is administered in the matrix in a pre-reduced activated state at sustained high doses (Patent Application PCT/GB01/03574), thus overtaking its physiological control mechanisms, it can suppress endothelial tube formation without cell toxicity in an *in vitro* co-culture angiogenesis model (Griffin et al 2002b). Following this sustained tTG-treatment, the ECM embedding the capillary vessels displays a high level of transglutaminase activity (measured *in situ* via fluorescein-cadaverine incorporation) and increased matrix stability.

Interestingly gene array analysis of differential gene expression during human capillary morphogenesis in 3D collagen matrices has classified tTG among the genes which are regulated during this process. Indeed tTG was found to be remarkably downregulated, approximately 4-fold at 8 hour and 10-fold at 24 and 48 hour of endothelial cell cultures in 3D collagen matrix (Bell et al 2001), thus confirming that lowered levels of tTG expression are required during the initial stages of angiogenesis.

tTG and abnormal healing leading to fibrosis and scarring

As outlined at the start of this review wound healing is characterised by three interrelated and overlapping phases: inflammation, tissue formation/stabilisation and tissue remodelling. However, once these phases are completed there must be resolution of the inflammatory response, clearance of the inflammatory cells and a return to normal ECM homeostasis. If the insult continues (eg diabetes, chronic infection, genetic disease, toxic exposure, chronic inflammation e.g. as a result of auto immunity) or alternatively the termination / resolution of part of the wound response fails to initiate correctly, a period of chronic wounding ensues that can lead to progressive scarring and fibrosis. In the major organs such as liver, heart and kidney this progressive scarring is the major cause (over 95%) of organ dysfunction and failure. The mechanisms underlying progressive

scarring have been the subject of intensive research over several decades, yet there is still no effective therapy for this treatment.

The observation that tTG may be involved in progressive scarring was first reported in the lung (Griffin et al. 1978), although similar observations have subsequently been reported in liver (Mirza et al. 1997; Grenard et al. 2001), heart (Small et al. 1999), vasculature (Bowness et al. 1994) and perhaps most extensively in the kidney (Johnson et al. 1997) (see fig 5 and fig 6). In 1978 using a paraquat induced model of pulmonary scarring we reported an upregulation of TG activity (Griffin et al. 1978). In a series of studies by Bowness and colleagues (Bowness et al. 1987; Bowness et al. 1989; Bowness and Tarr 1990; Bowness et al. 1994;) increased TG found in atherosclerotic plaques correlated with increases in the ϵ -(γ -glutamyl) lysine crosslink. TG mediated crosslinking was associated with stabilisation of the collagen III – lipoprotein interface surrounding the sclerotic plaque. Later Mirza (Mirza et al. 1997) and colleagues reported increased tTG in hepatic fibrosis with mRNA analysis showing an upregulation of tTG in most liver cell types. In later studies Small and colleagues (Small et al. 1999), using a transgenic mouse with enhanced cardiac tTG expression showed that those animals developed cardiomyopathy. In the kidney, we first reported changes in TG in tubular epithelial cells in renal scarring in a subtotal nephrectomy model that led to increased ϵ -(γ -glutamyl) lysine levels found predominantly in the tubulointerstitium (Johnson et al. 1997). Later studies demonstrated that this increase was due to an elevated synthesis and cellular export of tTG by these tubular cells (Johnson *et al* 1999). Similar studies in a streptozotocin model of early diabetic nephropathy further demonstrated the presence of increased levels of ϵ -(γ -glutamyl) lysine that were similarly located in the interstitial space, but also found in the glomerular basement membrane and in the expanding mesangial matrix with the mesangial cells being the primary source of tTG in the glomeruli (Skill et al. 2001). This study was particularly interesting since it showed that increased levels of tTG could be exported to the ECM independently of changes in tTG synthesis. More recently, we have been able to expand observations of tTG in kidney scarring to the clinical situation whereby 136 renal biopsies with varying degrees of scarring from a range of original etiologies were studied (Johnson et al. 2003). This

showed that changes in tTG and ϵ -(γ -glutamyl) lysine correlated exceptionally well with the degree of scarring and that changes were independent of the original disease.

The major problem with these changes observed for tTG in vivo in aberrant wound healing is that the insult is never removed, therefore the key question is whether these prolonged increases in tTG is one of the major causes in switching normal wound healing to pathological scarring or whether they are an attempt to minimise damage from a continuing insult. In order to address these issues we have recently undertaken pilot studies using irreversible site directed inhibitors of tTG in the subtotal nephrectomy model of renal scarring using direct intra-renal delivery from an implanted osmotic minipump (Johnson et al. 2003). Our preliminary data indicate that inhibition of TG activity from the initiation of the insult preserves both renal architecture and function and that the degree of scarring (including deposited collagen) is vastly reduced. Interestingly however, if one over inhibits TG activity this leads to an extensive infiltration by monocytic derived inflammatory cells further suggesting that TG may have a role in modulating the immune response. The actual mechanism as to how inhibition of TG leads to a reduction in scarring which is essentially a reduction in collagen deposition following tissue remodelling still remains an open question. Evidence suggests that the storage of latent TGF- β_1 through latent TGF- β binding protein 1 (LTBP-1) in the ECM (Taipale et al 1994) is an important early step in the proteolytic activation of TGF- β_1 . As previously eluded to, LTBP-1 is a substrate for tTG in vitro (Nunes et al 1997) and in cells in culture (Verderio et al 1999), and tTG may mediate both matrix storage and activation of TGF- β_1 . Both excess TGF- β and increased expression of tTG have been implicated in a number of fibroproliferative conditions (Griffin et al., 1979; Mirza et al., 1997; Johnson et al., 1997) Hence reducing tTG activity should in theory reduce the levels of TGF β_1 thus reducing collagen deposition by an indirect mechanism [See Fig 7] An alternative mechanism is that tTG mediated crosslinking of collagen and /or associated proteins has a direct effect on their deposition as previously eluded to earlier in this chapter.

In 1995 Kleman and colleagues (Kleman *et al* 1995) using a rhabdomyosarcoma cell line demonstrated that tTG was able to cause lysyl oxidase independent crosslinking of collagen V and XI leading to stabilisation of the fibrillar structure. Although similar studies have not been demonstrated for other collagen types the ability of tTG to crosslink collagen fibrils in the terminal maturation step of collagen deposition, thought to be the preserved role of lysyl oxidase, suggested that tTG might be able to modify the rate at which collagen is deposited. Such a step could be crucial in the scarring process since upto 95% of the collagen molecules which are normally produced in massive excess are degraded prior to their deposition. (Mays *et al* 1991). Hence any step which tips the balance towards matrix deposition is likely to have a major influence on ECM homeostasis.

If excessive crosslinking does occur in the ECM during progression of the diseased state, then by definition this makes qualitative changes to the matrix. This may not only alter some of the properties of the ECM, but may alter its resilience to enzymatic decay. There are several enzyme systems involved in the breakdown of the matrix, with plasmin, cathepsins and the matrix metalloproteinases (MMP) being the major players. Of these, the 18 membered MMP family is the most prominent, with sub classes of MMPs such as the gelatinases, stromelysin and interstitial collagenases targeting specific classes of ECM proteins. As referred to earlier, Kleman *et al* indicated that tTG caused intramolecular crosslinking within the collagen V & XI fibrils in the N and C termini of the collagen molecules. Interestingly this is the same region in which interstitial collagenases such as MMP 1 and MMP 8 target to excise the lysyl oxidase catalysed pyridinoline / pyrrole trivalent crosslinks that stabilise the collagen fibril (Batge *et al.* 1990; Wu *et al.* 1990; Hasty *et al.* 1993). Therefore if $\epsilon(\gamma\text{-glutamyl})$ lysine crosslinking occurred adjacent to the pyridinoline / pyrrole crosslinks then the removal of these lysyl oxidase catalysed bonds may not be sufficient to solubilise the collagen molecule essential for matrix turnover.

To test this hypothesis we initially employed a modification of the collagen fibril assay where isolated collagen 1 was formed into fibrils and crosslinked with tTG before exposure to MMP1. tTG crosslinked collagen 1 was 3 x less susceptible to the action of

MMP-1 than a normal collagen fibril, and even less susceptible if FN is crosslinked to the collagen fibril by tTG (Johnson et al. 1999).

In a more recent study we have added exogenous tTG to cultures of human dermal fibroblasts to mimic the release of tTG that occurs following exposure to damaging agents such as prolonged exposure to UVA. Our results indicate that increased levels of tTG that might be deemed pathological lead to an increase in collagen deposition and a slowed rate of collagen turnover which would contribute to the scarring process consistent with that of skin aging induced by solar radiation [Gross et al 2003]. Our preliminary studies with kidney tubular epithelial cells also indicate that increased expression of tTG in these cells brought about either via transfection or by exposure to high glucose levels typical of those found in diabetic nephropathy leads to changes in collagen deposition that may be independent of TGF β_1 levels.

Hence if tTG is able to enhance the rate of ECM deposition and/or restrict the rate of ECM decay as our preliminary data suggests, then overexpression and cellular release of the enzyme would promote ECM accumulation leading to rapid wound closure and maintenance of tissue integrity. If however, the insult is prolonged then the accumulation of tTg in the ECM becomes pathological leading to excessive scar formation and fibrosis.

These observations are consistent with and give further clarification to earlier findings that tTG activity is increased in hypertrophic scarring, resulting in excess-healing and accumulation of ϵ -(γ -glutamyl) lysine cross-links to form insoluble collagen matrices. Importantly the observation that this condition could be inhibited by 50 mM putrescine, a competitive primary amine substrate of transglutaminase that would reduce crosslinking, led to investigating the clinical effect of 50 mM putrescine in a eutectic vehicle (Fibrostat) which was studied in phase II clinical trial (Dolynchuk et al 1994 and 1996) The compound has so far reached Phase IIb clinical trial and represents a unique topical pharmaceutical preparations with an active pharmaceutical ingredient that reduces hypertrophic scarring.

Given the strong affinity of tTgase for FN (Jeong et al., 1995) and the high affinity of FN for other ECM proteins, it is possible that tTgase may also play a pivotal role in the cross-linking of other wound healing factors to the ECM, thus providing a further means of regulating the wound response.

Thymosin Beta 4 (T β 4) is the most abundant member of a family of highly conserved and extremely water-soluble 5 kDa polypeptides; it is expressed in most cell types and is regarded as the main intracellular G-actin sequestering, regulating the growth and differentiation of actin and playing a role in wound healing (Malinda et al 1999). There is increasing evidence for extracellular functions of T β 4, which increases endothelial cell adhesion and migration, stimulates angiogenesis and down regulates a number of inflammatory cytokines, and it was recently found that tissue transglutaminase can cross-links T β 4 to proteins such as fibrin and collagen (Huff et al 1999 and 2002). After activation of human platelets with thrombin, T β 4 is released and cross-linked by transglutaminase (factor XIIIa), thus accumulating at sites of clots and tissue damage, where it may contribute to wound healing, angiogenesis and inflammatory responses (Huff et al 2002).

T β 4 represents a novel class of drugs in development to accelerate the healing process, speed the growth of blood vessels, and decrease inflammation (Philp et al 2003). A Phase 1 clinical trial with a chemically synthesized copy of T β 4 has recently begun in 2003.

Conclusions

In summary (see Fig 7), following tissue injury, accumulation of tTG in the matrix of the surrounding area appears to lead to the intermolecular crosslinking of many ECM components (especially collagens and fibronectin), probably leading to their accelerated rate of deposition. During normal wound healing tTG transamidating activity is likely to be rapidly downregulated by binding to matrix proteins such as FN and by the oxidizing extracellular environment. Importantly, binding of tTG to FN may also form a complex with novel pro-survival characteristics which mediates cell signalling through the HSPG

class of transmembrane receptors. In addition, extracellular tTG may control the storage of latent TGF- β , thus influencing the activation of TGF- β , which is not only a major player in the inflammatory response, but also crucial in regulating ECM homeostasis via its regulation of MMP and TIMP synthesis.. In the initial insult to a tissue loss of Ca²⁺ homeostasis in cells could also promote rapid intracellular crosslinking by tTG providing an alternative fast mechanism to apoptosis for preventing loss of intracellular components and thus limiting the inflammatory response.

If however, the insult to the tissue is maintained leading to massive accumulation of both intracellular and extracellular levels of tTG then the preservation of tissue integrity leads to a pathological event promoting ECM accumulation and excessive tissue scarring.

Acknowledgements

Our work was partially supported by grant GR/L43688 (MG), and grant GR/521755/01 (MG and EV) from EPSRC, the award of a National Kidney Research Fund senior fellowship to TS Johnson (SF2/2000) National Kidney Research Fund grant (TSJ and MG) and the Wellcome Trust (MG and TSJ).

References

Aeschlimann D, Mosher D, Paulsson M. Tissue transglutaminase and factor XIII in cartilage and bone remodeling (1996) *Semin Thromb Hemost.* 22:437-443.

Aeschlimann, D. and Thommazy V (2000) Protein crosslinking in assembly and remodelling of extracellular matrices: the role of transglutaminases. *Connect. Tissue Res.* 41:1-27.

Agah A, Kyriakides TR, Lawler J, Bornstein P (2002) The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. *Am J Pathol* 161:831-839.

Akimov SS, Belkin AM (2001b) Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. *Blood* 98:1567-1576.

Akimov SS, Belkin AM (2001) Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFbeta-dependent matrix deposition *J Cell Sci* 114:2989-3000.

Akimov SS, Krylov D, Fleischman LF, Belkin AM (2000) Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. *J Cell Biol* 148:825-838.

Auld GC, Ritchie H, Robbie LA, Booth NA (2001) Thrombin upregulates tissue transglutaminase in endothelial cells: a potential role for tissue transglutaminase in stability of atherosclerotic plaque. *Arterioscler Thromb Vasc Biol* 21:1689-1694.

Balklava, Z, Verderio E, Collighan R, Gross S, Adams J, Griffin M (2002). Analysis of tissue transglutaminase function in the migration of Swiss 3T3 fibroblasts: the active-state conformation of the enzyme does not affect cell motility but it is important for its secretion. *J Biol Chem* 277:16567-16575.

Batge B, Notbohm H, Diebold J, Lehmann H, Bodo M, Deutzmann R and Muller PK (1990). "A critical crosslink region in human-bone-derived collagen type I. Specific cleavage site at residue Leu95." *Eur J Biochem* 192(1): 153-9.

Belkin AM, Akimov SS, Zaritskaya LS, Ratnikov BI., Deryugina EI, Strongin AY. (2001) Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion. *J Biol Chem* 276:18415-18422.

Bell SE, Mavila A, Salazar R, Bayless KJ, Kanagala S, Maxwell SA, Davis GE. (2001) Differential gene expression during capillary morphogenesis in 3D collagen matrices:

regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. *J Cell Sci* 114:2755-2773.

Bornstein P, Sage EH (2002) Matricellular proteins: extracellular modulators of cell function. *Curr Opin Cell Biol.* 14:608-616.

Bowness JM, Folk JE and Timpl R (1987)"Identification of a substrate site for liver transglutaminase on the aminopropeptide of type III collagen." *J Biol Chem* 262(3): 1022-4.

Bowness JM, and Tarr AH (1990). "Lipoprotein binding of crosslinked type III collagen aminopropeptide and fractions of its antigen in blood." *Biochem Biophys Res Commun* 170(2): 519-25.

Bowness JM, Tarr AH and Wiebe RI (1989). "Transglutaminase-catalysed cross-linking: a potential mechanism for the interaction of fibrinogen, low density lipoprotein and arterial type III procollagen." *Thromb Res* 54(4): 357-67.

Bowness JM, Tarr AH, Wong T (1988) Increased transglutaminase activity during skin wound healing in rats. *Biochim Biophys Acta* 967:234-240.

Bowness JM, Venditti M, Tarr AH and Taylor JR (1994). "Increase in epsilon(gamma-glutamyl) lysine crosslinks in atherosclerotic aortas." *Atherosclerosis* 111(2): 247-53.

Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K, Scheel_Toellner D, Simmons DL, Akbar AN, Lord JM, Salmon M. (1999) RGD peptides induce apoptosis by direct caspase-3 activation. *Nature* 397: 534-539.

Burridge K, Chrzanowska-Wodnicka M (1996) Focal adhesions, contractility, and signalling. *Annu Rev Cell Dev Biol* 12: 463-518.

Candi E, Oddi S, Paradisi A, Terrinoni A, Ranalli M, Teofoli P, Citro G, Scarpato S, Puddu P, Melino G (2002). Expression of transglutaminase 5 in normal and pathologic human epidermis. *J Invest Dermatol* 119:670-677.

Cocuzzi ET, Chung SI (1986) Cellular transglutaminase. Lung matrix-associated transglutaminase: characterization and activation with sulfhydryls. *J Biol Chem* 261:8122-8127.

Cordella-Miele E, Miele L, Beninati S, Mukherjee AB (1993) Transglutaminase-catalyzed incorporation of polyamines into phospholipase A2. *J Biochem (Tokyo)* 113:164-173.

Cordella-Miele E, Miele L, Mukherjee AB (1990) A novel transglutaminase-mediated post-translational modification of phospholipase A2 dramatically increases its catalytic activity. *J Biol Chem.* 265:17180-17188.

Crowe MJ, Doetschman T, Greenhalgh DG (2000) Delayed wound healing in immunodeficient TGF-beta 1 knockout mice. *J Invest Dermatol* 115:3-11.

Philp D, Badamchian M, Schermeta B, Nguyen M, Goldstein AL, Kleinman HK, (2003) Thymosin T β 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. *Wound Rep Reg*, 19-24

Davis GE, Bayless KJ, Davis MJ, Meininger GA (2000) Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. *Am J Pathol* 156:1489-1498.

De Laurenzi V, Melino G (2001) Gene disruption of tissue transglutaminase. *Mol Cell Biol* 21:148-155.

Desmouliere A, Redard M, Darby I, Gabbiani G (1995) Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. *Am J Pathol.* 146:56-66.

Dolynchuk KN, Bendor-Samuel R, Bowness JM (1994) Effect of putrescine on tissue transglutaminase activity in wounds: decreased breaking strength and increased matrix fucoprotein solubility. *Plast Reconstr Surg* 93:567-573.

Dolynchuk KN, Ziesmann M, Serletti JM. (1996) Topical putrescine (Fibrostat) in treatment of hypertrophic scars: phase II study. *Plast Reconstr Surg* 97:117-123.

Fesus L, Piacentini M (2002) Transglutaminase 2: an enigmatic enzyme with diverse functions. *Trends Biochem Sci.* 27:534-539.

Fesus L, and Thomazy V (1988). "Searching for the function of tissue transglutaminase: its possible involvement in the biochemical pathway of programmed cell death." *Adv Exp Med Biol* 231: 119-34.

Fisher M, Skill N, Huang L, Rustom R, Nahas ME, Griffin M and Johnson T. (2002). "Factors Associated with Renal Scarring That Lead to Changes in Tissue Transglutaminase (tTg) Expression and Release by Renal Tubular Epithelial Cells." *Minerva Biotechnologica* 14(2): 223.

Fogerty FJ, Akiyama SK, Yamada KM, Mosher DF (1990). Inhibition of binding of fibronectin to matrix assembly sites by anti-integrin (alpha 5 beta 1) antibodies. *J Cell Biol.* 111:699-708.

Frisch SM, Screaton RA (2001) Anoikis mechanisms. *Curr. Opin. Cell Biol.*13:555-562.

Frisch SM, Vuori K, Ruoslahti E, Chan Hui PY (1996) Control of adhesion-dependent cell survival by focal adhesion kinase. *J Cell Biol* 134:793-799.

Gallucci RM, Simeonova PP, Matheson JM, Kommineni C, Guriel JL, Sugawara T, Luster MI. (2000) Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. *FASEB J* 14:2525-2531.

Gaudry CA, Verderio E, Jones RA, Smith C, Griffin M (1999b) Tissue transglutaminase is an important player at the surface of human endothelial cells: evidence for its externalization and its colocalization with the beta(1) integrin. *Exp Cell Res* 252:104-113.

Gaudry CA., Verderio E, Aeschlimann D, Cox A, Smith A, Griffin M (1999) Cell surface localisation of tissue transglutaminase is dependent on a fibronectin-binding site in its N-terminal beta-sandwich domain. *J Biol Chem* 274:30707-30714.

George MD, Vollberg TM, Floyd EE, Stein JP, Jetten AM (1990) Regulation of transglutaminase type II by transforming growth factor-beta 1 in normal and transformed human epidermal keratinocytes. *J Biol Chem* 265:11098-11104.

Grenard P, Bates MK, Aeschlimann D (2001) Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. *J Biol Chem* 276: 33066-33078.

Grenard P, Bresson-Hadni S, El Alaoui S, Chevallier DA, Vuitton DA, and Ricard-Blum S. (2001). "Transglutaminase-mediated cross-linking is involved in the stabilization of extracellular matrix in human liver fibrosis." *J Hepatol* 35(3): 367-75.

Griffin M, Casadio R, Bergamini CM (2002) Transglutaminases: nature's biological glues. *Biochem J.* 368: 377-396.

Griffin M, Jones RA, Parry J, Balklava Z, Johnson T, Kotsakis P (2002b) Tissue transglutaminase in tumour growth and progression: a novel strategy for tumour therapy. *Minerva Biotechnologica* 14 pp 213.

Griffin M, Smith LL, and Wynne J. (1979). "Changes in transglutaminase activity in an experimental model of pulmonary fibrosis induced by paraquat." *Br J Exp Pathol* 60: 653-661.

Gross SR, Balklava Z, Griffin M (2003) Importance of tissue transglutaminase in repair of extracellular matrices and cell death of dermal fibroblasts after exposure to a solarium ultraviolet a source. *J Invest Dermatol.* 121:412-423.

Gschwendt M, Dieterich S, Rennecke J, Kittstein W, Muller HJ, Johannes FJ (1996) Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase C isoenzymes. *FEBS Lett* 392:77-80.

Hadden HL, Henke CA (2000) Induction of lung fibroblast apoptosis by soluble fibronectin peptides. *Am J Respir Crit Care Med.* 162: 1553-1560.

Harding KG, Morris HL, Patel GK (2002) Science, medicine and the future: healing chronic wounds. *BMJ* 324: 160-163.

Haroon Z A, Hettasch J M, Lai T S, Dewhirst M W, and Greenberg C S (1999). Tissue transglutaminases expressed active and directly involved in rat dermal wound healing and angiogenesis *FASEB J.* 13, 1787 – 1795.

Hasty KA, Wu H, Byrne M, Goldring MB, Seyer JM, Jaenisch R, Krane SM, and Mainardi CL. (1993). "Susceptibility of type I collagen containing mutated alpha 1(1) chains to cleavage by human neutrophil collagenase." *Matrix* 13(3): 181-6.

Heath DJ, Downes S, Verderio E, Griffin M (2001) Characterization of tissue transglutaminase in human osteoblast-like cells *J Bone Miner Res.* 16:1477-1485

Huff T, Otto AM, Muller CS, Meier M, Hannappel E (2002) Thymosin beta4 is released from human blood platelets and attached by factor XIIIa (transglutaminase) to fibrin and collagen. *FASEB J* 16: 691-696.

Huff T; Ballweber E; Humeny A; Bonk T; Becker C; Muller CS; Mannherz HG; Hannappel E (1999) Thymosin Beta(4) Serves as a Glutaminyl Substrate of Transglutaminase. Labeling with Fluorescent Dansylcadaverine Does Not Abolish Interaction with G-actin. *FEBS Lett* 464:14-20.

Ikura K, Shinagawa R, Suto N, Sasaki R (1994) Increase caused by interleukin-6 in promoter activity of guinea pig liver transglutaminase gene. *Biosci Biotechnol Biochem* 58:1540-1541.

Ilan N, Mahooti S, Madri JA (1998) Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. *J Cell Sci.* 111:3621-3631.

Isobe T, Takahashi H, Ueki S, Takagi J, Saito Y (1999). Activity-independent cell adhesion to tissue-type transglutaminase is mediated by alpha4beta1 integrin. *Eur J. Cell Biol* 78:876-883.

Jeong JM, Murthy SN, Radek JT, Lorand L (1995). The fibronectin-binding domain of transglutaminase. *J Biol Chem* 10:5654-5658.

Johnson, T S, El-Koraie AF, Skill NJ, Baddour NM, El Nahas AM, Njloma M, Adam AG and Griffin M. (2003). "Tissue transglutaminase and the progression of human renal scarring." J Am Soc Nephrol 14(8): 2052-62.

Johnson T, Fisher M, Haylor J, Hau Z, Jones R, Coutts I, Saint R, El-Nahas MA and Griffin M. (2003). "Renal Inhibition of Transglutaminase Activity Ameliorates Scarring in the Rat 5/6th Subtotal Nephrectomy Model." Proceedings of the National Kidney Research Fund Fellows Day, Keele University, April 2003.

Johnson T, Fisher M, Wang B, Mc-Ardle F, Jackson M, Bone J and Rustom R. (2002). "Up regulation and cellular release of transglutaminase in a novel model of chronic acidosis using porcine proximal tubular epithelial cells." Proceedings of the spring Renal Association meeting, York University, UK Kidney Int. on-line abstracts via www.renal.org.

Johnson T S, Griffin M, Thomas GL, Skill J, Cox A, Yang B, Nicholas B, Birckbichler PJ, Muchaneta-Kubara C and El Nahas AM. (1997). "The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis." J Clin Invest 99(12): 2950-60.

Johnson TS, Scholfield CI, Parry J, Griffin M (1998) Induction of tissue transglutaminase by dexamethasone: its correlation to receptor number and transglutaminase-mediated cell death in a series of malignant hamster fibrosarcomas. Biochem J. 331:105-112.

Johnson TS, Skill NJ, El Nahas AM., Oldroyd SD, Thomas G., Douthwaite JA, Haylor, JL, Griffin M (1999) Transglutaminase transcription and antigen translocation in experimental renal scarring. J Am Soc Nephrol 10:2146-2157.

Jones RA., Nicholas B, Mian S, Davies PJ, Griffin M (1997). Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin. *J Cell Sci* 110: 2461-2472.

Kapila, YL, Wang S, Johnson PJ. (1999) Mutations in the heparin binding domain of fibronectin in cooperation with the V region induce decreases in pp125(FAK) levels plus proteoglycan-mediated apoptosis via caspases. *J Biol. Chem* 274:30906-30913.

Kleman, J. P., D. Aeschlimann, M. Paulsson and M. van der Rest (1995). "Transglutaminase-catalyzed cross-linking of fibrils of collagen V/XI in A204 rhabdomyosarcoma cells." *Biochemistry* 34(42): 13768-75.

Kuncio GS, Tsyganskaya M, Zhu J, Liu SL, Nagy L, Thomazy V, Davies PJ, Zern MA (1998) TNF-alpha modulates expression of the tissue transglutaminase gene in liver cells. *Am J Physiol* 274:G240-245.

Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang Z, Lin MT, Danielson KG, Iozzo RV, LaMarca M, McKinney CE, Ginns EI, Bornstein P (1998) Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. *J Cell Biol.* 140:419-430.

LeMosy EK, Erickson HP, Beyer WF, Radek JT, Jeong JM, Murthy SN, Lorand L (1992). Visualization of purified fibronectin-transglutaminase complexes. *J Biol Chem* 267:7880-7885.

Li J, Zhang YP, Kirsner RS. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix (2003) *Microsc Res Tech* 60:107-114.

Li X, Verderio E, Griffin M (2002) Effects of tissue transglutaminase expression on cell stress by 3-nitropropionic acid (3-NP) *Minerva Biotechnologica* 14 pp 209.

Liu S, Cerione RA, Clardy J (2002) Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. *Proc Natl Acad Sci. USA* 99:2743-2747.

Liu S, Cerione RA., Clardy J (2002) Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. *Proc. Natl. Acad. Sci. USA* 99:2743-2747.

Lorand L, Graham RM (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. *Nat Rev Mol Cell Biol.* 4:140-156.

Malinda KM; Sidhu GS; Mani H; Banaudha K; Maheshwari RK; Goldstein AL; Kleinman HK (1999) Thymosin Beta 4 Accelerates Wound Healing. *J Invest Dermatol.* 113:364-368.

Martinez J, Chalupowicz DG, Roush RK, Sheth A, Barsigian C (1994) Transglutaminase-mediated processing of fibronectin by endothelial cell monolayers. *Biochemistry* 33:2538-2545.

Mays, P. K., R. J. McAnulty, J. S. Campa and G. J. Laurent (1991). "Age-related changes in collagen synthesis and degradation in rat tissues. Importance of degradation of newly synthesized collagen in regulating collagen production." *Biochem J* 276(Pt 2): 307-13.

McCawley LJ., Matrisian LM (2001) Matrix metalloproteinases: they're not just for matrix anymore! *Curr Opin Cell Biol*13: 534-540.

Mearns B, Nanda N, Michalicek J, Iismaa S, Graham R. (2002) Impaired wound healing and altered fibroblast cytoskeletal dynamics in Gh knockout mice *Minerva Biotechnologica* 14 pp 218.

Mirza A, Liu SL, Frizell E, Zhu J, Maddukuri S, Martinez J, Davies P, Schwarting R, Norton P, Zern MA (1997) A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-Kb. *Am J Physiol* 272: 6281-6288.

Mitchell J, Auld GC, Koikkalainen JS, Ritchie H, Booth NA (2002) *Minerva Biotechnologica* 14 pp 211.

Muro AF, Chauhan AK, Gajovic S, Iaconcig A, Porro F, Stanta G, Baralle FE (2003) Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. *J Cell Biol.* 162:149-160.

Nanda N, Iismaa SE., Owens WA., Husain A, Mackay F, Graham RM. (2001) Targeted inactivation of Gh/tissue transglutaminase II. *J Biol Chem* 276:20673-20678.

Nicholas B, Smethurst P, Verderio E, Jones R, Griffin M (2003). Cross-linking of cellular proteins by tissue transglutaminase during necrotic cell death: a mechanism for maintaining tissue integrity. *Biochem J* 371:413-422.

Nomura, Y., S. Toki, Y. Ishii and K. Shirai (2001). "Effect of transglutaminase on reconstruction and physicochemical properties of collagen gel from shark type I collagen." *Biomacromolecules* 2(1): 105-10.

Nunes I, Gleizes PE, Metz CN, Rifkin DB (1997) Latent transforming growth factor- β_1 binding protein domains involved in activation and transglutaminase dependent crosslinking of latent transforming growth factor- β_1 . *J Cell Biol* 136: 1151-1163
Proc. Natl. Acad. Sci. USA 96:2805-2810.

Radek JT., Jeong JM, Murthy SN, Ingham KC, Lorand L (1993). Affinity of human erythrocyte transglutaminase for a 42-kDa gelatin-binding fragment of human plasma fibronectin. *Proc. Natl. Acad. Sci. USA.* 90:3152-3156.

Raghunath M, Hopfner B, Aeschlimann D, Luthi U, Meuli M, Altermatt S, Gobet R, Bruckner-Tuderman L, Steinmann B (1996) Cross-linking of the dermo-epidermal junction of skin regenerating from keratinocyte autografts. Anchoring fibrils are a target for tissue transglutaminase. *J Clin Invest.* 1 98:1174-1184.

Ritchie H, Lawrie LC, Crombie PW, Mosesson MW, Booth NA (2000) Cross-linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen). *J Biol Chem.* 275:24915-2420.

Ritter SJ, Davies PJ.(1998) Identification of a transforming growth factor-beta1/bone morphogenetic protein 4 (TGF-beta1/BMP4) response element within the mouse tissue transglutaminase gene promoter. *J. Biol. Chem.* 271:12798-12806.

Saoncella S, Echtermeyer F, Denhez F, Nowlen JK, Mosher DF, Robinson SD, Hynes RO, Goetinck PF (1999) Syndecan-4 signals cooperatively with integrins in a Rho-dependent manner in the assembly of focal adhesions and actin stress fibers.

Sechler JL, Schwarzbauer JE (1998) Control of cell cycle progression by fibronectin matrix architecture. *J. Biol. Chem.* 273:25533-25536.

Shah M, Revis D, Herrick S, Baillie R, Thorgeirson S, Ferguson M, Roberts (1999) A. Role of elevated plasma transforming growth factor-beta1 levels in wound healing. *Am J Pathol* 154:1115-1124.

Singer AJ, Clark RA (1999) Cutaneous wound healing. *N Engl J Med* 341:738-746.

Skill N, Griffin M, Coutts I, Fisher M, Huang L, Nahas AE and Johnson T. (2003). "Inhibition of Transglutaminase (Tg) Activity Reduces The Extracellular Matrix (ECM) Accumulation Characteristic of High Glucose Levels in Proximal Tubular Cells." Proceedings of the spring Renal Association meeting, Keele University, UK: Kidney Int. on-line abstracts via www.renal.org.

Skill NJ, Griffin M, El Nahas AM, Sanai T, Haylor JL, Fisher M, Jamie MF, Mould NN and Johnson TS. (2001). "Increases in renal epsilon-(gamma-glutamyl)-lysine crosslinks result from compartment-specific changes in tissue transglutaminase in early experimental diabetic nephropathy: pathologic implications." *Lab Invest* 81(5): 705-16.

Small K, Feng JF, Lorenz J, Donnelly ET, Yu A, Im MJ, Dorn GW 2nd and Liggett SB. (1999). "Cardiac specific overexpression of transglutaminase II (G(h)) results in a unique hypertrophy phenotype independent of phospholipase C activation." *J Biol Chem* 274(30): 21291-6.

Smethurst PA, Griffin M (1996) Measurement of tissue transglutaminase activity in a permeabilized cell system: its regulation by Ca²⁺ and nucleotides. *Biochem J.* 313: 803-808.

Sohn J, Kim TI, Yoon YH, Kim JY, Kim SY (2003) Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. *J Clin Invest* 111:121-128.

Suto N, Ikura K, Sasaki R (1993) Expression induced by interleukin-6 of tissue-type transglutaminase in human hepatoblastoma HepG2 cells. *J Biol Chem.* 268:7469-7473.

Szondy Z, Sarang Z, Molnar P, Nemeth T, Piacentini M, Mastroberardino PG, Falasca L, Aeschlimann D, Kovacs J, Kiss I, Szegezdi E, Lakos G, Rajnavolgyi E, Birckbichler PJ, Melino G, Fesus L (2003) Transglutaminase 2^{-/-} mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. *Proc Natl Acad Sci U S A.* 100:7812-7817.

Taipale J, Miyazono K, Heldin C-H, Keski-Oja J (1994) Latent transforming growth factor- β_1 associates to fibroblast extracellular matrix via latent TGF- β_1 binding protein. *J Cell Biol* 124: 171-181.

Upchurch HF, Conway E, Patterson MK Jr, Maxwell MD (1991) Localization of cellular transglutaminase on the extracellular matrix after wounding: characteristics of the matrix bound enzyme. *J Cell Physiol* 149:375-382.

Verderio E, Gaudry CA, Gross S, Smith S, Downes S, Griffin M (1999) Regulation of cell surface tissue transglutaminase: effects on matrix storage of latent transforming growth factor β_1 -binding protein-1. *J Histochem Cytochem* 47:1417-1432.

Verderio E., Nicholas B, Gross S, Griffin M (1998) Regulated expression of tissue transglutaminase in Swiss 3T3 fibroblasts: effects on the processing of fibronectin, cell attachment and cell death *Exp Cell Res* 239:119-138.

Verderio, EAM, Telc, D, Okoye A, Melino G, Griffin M (2003) A novel RGD-independent cell adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis. *J Biol Chem*. Published on line.

Wilcox-Adelman SA, Denhez F, Goetinck PF (2002) Syndecan-4 modulates focal adhesion kinase phosphorylation. *J Biol Chem* 277:32970-32977.

Woods A, Couchman JR. (2001) Syndecan-4 and focal adhesion function. *Curr Opin Cell Biol* 13:578-583.

Wu H, Byrne M H, Stacey A, Golding J R, et al (1990) Generation of collagenase-resistant collagen by site directed mutagenesis of marine pro alpha 1 (I) collagen gene *PNAS* 87, 5888 – 5892.

Zhang Z, Vezza R, Plappert T, McNamara P, Lawson JA, Austin S, Pratico D, Sutton MS, FitzGerald GA (2003) COX-2-dependent cardiac failure in Gh/tTG transgenic mice. *Circ Res.* 92:1153-1161.

Corresponding authors address: School of Science, Nottingham Trent University,
Clifton Lane, Nottingham NG11 8NS-UK. Tel.: +44 (0) 115 848 6670. Fax: +44 (0) 115
848 6636.

Figure legends

Fig. 1

Complex interrelations between the actions of tTG (transglutaminase -2) and the repair process

The scheme depicts the phases of cutaneous wound healing, however most of the repair process applies to other tissues.

Abbreviations: FXIIIa factor XIII subunit a; kTG, keratinocyte transglutaminase; tTG, epidermal transglutaminase; TG5, transglutaminase type 5 (Grenard et al 2001; Candi et al 2003); sPLA2, secretory isoform of Phospholipase A2; FN, fibronectin; ECM, extracellular matrix; MMP, matrix metalloproteinase; PA, plasminogen activator; PAI-2, plasminogen activator inhibitor 2; TGF- β , transforming growth factor β ; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; FGF, fibroblast growth factor; DEJ, dermo-epidermal junction.

Fig. 2

Time course of tTG activity in wounded cell monolayers of Swiss 3T3 cells

(A) ECV 304 cells were wounded using a sterile plastic pipette tip. They were then incubated in the presence of the primary amine tTG substrate biotinylated cadaverine (BTC) for 20 min and detected by DAB stain and visualised using light microscopy. Control, no BTC (panel i). +BTC (panel ii). +BTC and 5 mM putrescine (panel iii). Cells were counterstained with propidium iodide. (B) ECV 304 cells wounded as described above and then incubated in the presence of BTC and incorporation revealed using streptavidin-FITC. x10 magnification using conventional fluorescence microscopy (panel i). x 63 magnification using confocal laser microscopy, showing a 1 μ m section through the middle of the cells (panel ii). Cells are counterstained with propidium iodide. (C) Swiss 3T3 cells (clone TG3) induced to overexpress tTG and wounded as previously described in the presence of the primary amine tTG substrate fluorescein-cadaverine and then examined after 20 min at x 10 magnification (panel i) and x 40 magnification (panel ii) using a Leica TCSNT confocal laser microscope. The micrographs shown are 1 μ m sections through the middle of these cells. Arrows indicate the direction of wounding,

and scale bars represent 10 μ m. Taken from Nicholas *et al* (2003) with permission of authors and permission of the Biochemical Society.

Fig. 3

In vitro migration analysis of transfected Swiss 3T3 fibroblasts (clone TG3).

Fibroblasts non-induced (A) and induced (B) to overexpress tTG by withdrawal of tetracycline from the medium, were cultured in DMEM with 10% FCS until confluency. In vitro wound clousres test were performed by introducing a wound in the monolayers with a plastic tip (diamter 1 mm). The monolayers were then covered with fresh medium and incubated for a 20-h period. Following fixation of cells and staining with crystal violet the number of cells migrated in the cleared area was assessed by examining cells“in blind”. Bar, 20 μ M. Quantifications of the migrated cells (C) showed that cells over-expressing tTG migrated into the wound bed significantly less ($p < 0.05$) compared with non-induced controls.

Results are form a typical triplicate experiment.

Fig. 4

Confocal laser fluorescence microscopy of RGD-independent focal adhesion in response to tTG-FN.

Primary human osteoblasts were seeded in 0.79 cm²-wells of chamber slides (8×10^4 /well) previously coated with FN and FN with immobilised tTG as described (Verderio *et al* 2003) and allowed to adhere for ~ 20 minutes. Focal adhesions formed by cells on FN in the presence (A) or absence of RGD peptide (B) and on tTG-FN with (C) or without (D) RGD peptide, were detected on fixed and pereabilised cells by indirect immunofluorescent staining for vinculin, using a monoclonal anti-vinculin antibody followed by secondary antibody conjugated to FITC. After nuclear staining with propidium iodide, cells were imaged by confocal fluorescent microscopy using a Leica TCSNT confocal laser microscope system, equipped with an argon/krypton laser adjusted at 488 nm for fluorescein excitation. Bar, 10 μ M.

Fig. 5

Involvement of tissue transglutaminase in renal scarring.

Panels A-D. Tissue Transglutaminase staining (red) in Normal Glomeruli (A) and cortical tubulointerstitium (B) compared to that in renal scarring resulting from Focal Segmental Glomerulosclerosis. Arrow 1 indicates increased staining in the expanded tubulointerstitium, arrow 2 the mesangial matrix/glomerular basement membrane and arrow 3 periglomerular.

Panels E-F $\epsilon(\gamma\text{-glutamyl})$ lysine staining (red) in biopsies from implanted allografts (Glomeruli (E) and cortical tubulointerstitium (F)) compared to that in scarred grafts resulting from chronic rejection. Arrows indicate as in panels A-D.

Panels I-L. Transglutaminase in situ activity (red) in normal rat kidney (I) and that from the 5/6th subtotal nephrectomy model of renal scarring (J-L). Panel K excludes autofluorescent emissions (green) showing renal morphology. Arrow 4 shows activity is strongest peritubular in the tubular basement membrane and that tTg in the expanded ECM loses most of its activity.

Panels M-Q. Tissue transglutaminase in situ hybridisation (black) in normal rat kidney (M) and that from a 5/6th subtotal nephrectomy model of renal scarring (N,O). Arrow 5 shows that proximal tubular cells are the predominant source of tTg in renal scarring, although arrow 6 indicates isolated patches of interstitial cells (Macrophages or myofibroblasts) are also able to synthesise tTG. Panel P shows a glomeruli from a patient with crescentic nephritis with tTG synthesis within the scarring crescent (arrow 7) (myofibroblasts) and panel Q shows mesangial cell synthesis in a patient with mesangial proliferative glomerulonephritis.

Fig 6

Correlation of tissue transglutaminase and protein crosslinking to renal scarring.

Quantification of staining for soluble tTG (A), insoluble tTG (B) and $\epsilon(\gamma\text{-glutamyl})$ lysine staining (C) in 136 renal patients from a range of initial aetiologies correlated to the level of renal scarring as assessed by point counting of Masson's Trichrome stained sections. Insoluble tTG and $\epsilon(\gamma\text{-glutamyl})$ lysine staining were measured using emission intensities from confocal microscopy, whereas soluble tTG was assessed by point counting.

Fig 7

Importance of tTG in the maintenance of tissue integrity following cell stress/injury

Tissue TG is normally in the extracellular matrix in relatively low amounts depending on the tissue. Following stress or insult, up-regulation of tTG often occurs, resulting in further enzyme externalized into the matrix. Insult leading to cell damage can also lead to increased tTgase leaking into the matrix. This is accompanied by the massive intracellular cross-linking of the tTgase containing dying cells following loss of Ca^{2+} homeostasis. Once increased in the matrix, the enzyme has both direct and indirect effects on the matrix, either through direct protein cross-linking leading to matrix stabilization or indirectly via the activation of matrix-bound $\text{TGF}\beta_1$ leading to matrix deposition. Matrix-bound tTG can also act as an independent cell-adhesion protein when bound to fibronectin preventing cell death by anoikis. The end result is would healing and maintenance of tissue integrity. Abbreviations: tTG, tissue transglutaminase MMP, Matrix Metalloproteinase; TIMP, tissue inhibitor of matrix metalloproteinase; LTBP, Latent TGFB, binding protein; LAP, Latency associated peptide.

A)

i)



ii)




iii)




B) i)



ii)



C) i)




ii)




Non induced (TG3 +tet)

Induced (TG3 +tet)




C




+ RGD peptide


A




B



C




D




FN
matrix


tTG-FN
matrix



A



B



C

